Moderna's Latest Move May be Key to COVID-19 Vaccine Market Dominance
Moderna (NASDAQ: MRNA) may already seem like a market leader. The biotech company's COVID-19 vaccine was only the second to earn an emergency use authorization (EUA) from the Food and Drug Administration, shortly after Pfizer and partner BioNTech garnered one for BNT162b2. In the months since, the U.S. has administered more than 54 million doses of the Moderna vaccine alone. And the Biden administration signed additional deals to buy enough Moderna and Pfizer doses to vaccinate the entire U.S. population.
But these companies are not yet able to cater to the whole potential market. The FDA has only authorized their vaccines -- and the recently approved Johnson & Johnson inoculation -- for use in adults.
This week, however, Moderna became the first to launch a COVID-19 vaccine trial in children ages 6 months through 11 years old. And its speed here might give it a sales edge.
Source Fool.com
